iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-5
Go back to iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-5| (NASDAQ: DTIL) | Delayed: 6.85 +0.11 (1.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.74 | 52 Week High | $ | |||
| Open | $6.78 | 52 Week Low | $ | |||
| Day High | $7.02 | P/E | N/A | |||
| Day Low | $6.57 | EPS | $ | |||
| Volume | 91,645 | |||||
